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Summary
Background In recent years a multiplex real-time PCR
(SeptiFast) has been introduced, allowing detection of
25 common blood pathogens considerably faster than
conventional blood culture.
Methods SeptiFast was applied routinely in addition
to blood culture in cases of critically ill patients with
fever and other signs of severe systemic infections. In
this study data of 470 episodes were retrospectively
analysed to assess the impact of various parameters,
such as clinical indications, assigning ward and an-
timicrobial treatment on test outcome using a multi-
variate logistic model.
Results After exclusion of microorganisms classified
as contaminants, the concordance between SeptiFast
and blood culture was 85.5%. SeptiFast detected 98
out of 120, while blood culture merely found 63 out of
120 potential pathogens. In comparison to blood cul-
ture, SeptiFast showed considerably higher positivity
rates in sepsis, pneumonia and febrile immunosup-
pression and a lower rate in endocarditis. The highest
positivity and concordance between tests was shown
in patients from the emergency room (P = 0.007).
Conclusions The results obtained in this study are
similar to those from prospective settings confirming
the robustness of the SeptiFast assay in routine use.
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Our data suggest that SeptiFast is a valuable add-on
to blood culture and may increase the diagnostic effi-
ciency of a microbiological laboratory.
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Introduction
In 2003 sepsis was estimated to be the thirdmost com-
mon cause of death overall, and its incidence is still
rising [1–4]. Fatality rates range from 10% for chil-
dren to 38.4% for elderly people, and sepsis accounts
for approximately 30% of healthcare costs in intensive
care units (ICU) [5].
Blood culture (BC) still is the gold standard for
microbiological sepsis diagnosis [6–8]; however, this
method lacks sensitivity, especially for slowly growing
or fastidious microorganisms and fungi. Substantial
time delays due to impaired growth kinetics of blood
microorganisms after antimicrobial treatment, low
initial pathogen load and volume of specimen inoc-
ulated, are frequently observed [9]. Numerous non-
infectious conditions can mimic sepsis, and the rapid
detection of the causative pathogen is of particular
importance since therapy and outcome differ greatly
between patients with sepsis and those with non-
infectious conditions. While timely administration
of adequate antimicrobial therapy is of paramount
importance for the survival of patients with sepsis,
inappropriate antibiotic therapy is not only associated
with reduced survival rates but also with increasing
antibiotic resistance, toxicity, costs and longer hos-
pital stays [10–20]. To meet the need for faster mi-
crobiological diagnostics, other methods have been
introduced into routine clinical laboratories, includ-
ing improved culture media, automated blood culture
systems, and molecular tests [21, 22]. SeptiFast (SF;
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Roche Diagnostics, Mannheim, Germany) was the
first real-time multiplex polymerase chain reaction
(PCR) test for whole blood samples. It covers the 19
most frequent bacterial and 6 most common fungal
pathogens of bloodstream infections. Originally de-
veloped and applied for patients with sepsis [23–34],
it is currently also used for other indications, e. g. pa-
tients with febrile neutropenia, endocarditis, fever of
unknown origin (FUO) and invasive aspergillosis [22,
29, 35–38]. With a 5-h run time, SF is considerably
faster than conventional BC testing [24, 39, 40]. The
SF test was introduced into the daily clinical routine
of our institution as an add-on to the conventional
laboratory sepsis diagnostics. During the first 3 years
paired BC and SF testing was implemented because
clinical data regarding the performance of SF were
sparse at that time. In the present study, we retro-
spectively analysed SF and BC results of this period
from patients with sepsis and/or evidence of other se-
vere systemic infectious diseases in association with
parameters, such as clinical indications, ward and
antimicrobial therapy. For a subset of ICU patients
the impact of positive results on total hospital as well
as ICU stay and mortality rate was also investigated.
Patients, materials and methods
Data acquisition
This study was conducted as a retrospective obser-
vational study and was approved by the institutional
review board of the Medical University Vienna and
performed in accordance with the ethical standards
as laid down in the 1964 Declaration of Helsinki and
its later amendments. For this type of study informed
consent is not required. Data were collected from
cases analysed at the Division of Clinical Microbiol-
ogy of Vienna’s General Hospital during a 3-year pe-
riod (2007–2010). Patients were included in the study
only if both BC and SF analyses were performed; spec-
imens for BC and SF testing had to be taken during the
same blood draw or within 24h of each other. All clini-
cal data were extracted from the information provided
on test request forms and the patient medical records.
Indications were sepsis, endocarditis, FUO, pneumo-
nia and immunosuppression (e. g. due to solid organ
or bone marrow transplantation or hematological ma-
lignancies). Test results from patients’ other microbi-
ological samples (OMS; other blood cultures, speci-
mens from central venous catheters, the lower res-
piratory tract, surgical sites, intra-abdominal swabs,
urine, other body fluids and tissue specimens) were
taken into consideration only if collected within 2 days
of the blood draw for SF/BC. Antibiotic treatment was
considered relevant if it had been administered within
24 h before testing. Clinical wards submitting the sam-
ples were internal, surgical, ICUs (surgical and inter-
nal), the emergency department, and outpatient units.
If common contaminants of the resident skin flora,
e. g. coagulase-negative staphylococci (CoNS) were
detected by BC, they were regarded as relevant mi-
croorganisms only after the consideration of certain
clinical conditions (e.g. endocarditis and central ve-
nous catheter associated infections) in conjunction
with laboratory data (time to positivity of the BC ≤
24 h and growth of the same microorganism in both
aerobic and anaerobic bottles in the case of a sin-
gle BC set, growth in multiple BC sets from the same
blood draw, or growth in OMS e. g. culture of the cen-
tral venous catheter).
When detected by the SF system software, CoNS
were considered to be relevant if the above-named
clinical conditions were met. In some cases, CoNS de-
tection was associated with a low peak during melting
curve analysis following PCR, which was not identified
by the software. In these cases, after manual interpre-
tation of the data, the CoNS were considered relevant
if they were also identified by BC and met the other
criteria described.
Laboratory procedures
The BC samples each consisted of an aerobic and
anaerobic bottle (usually 1–3 sets of the same episode).
The BC samples were incubated at 36.5–37 °C for up
to 7 days in the semi-automated continuous monitor-
ing BC system BacT/ALERT 3D (BioMérieux, Marcy
l’Etoile, France). Gram staining and subcultures on
solid media were performed from positive BCs. Iso-
lates were then identified via standard microbiologi-
cal methods, Vitek II (BioMerieux), or matrix-assisted
laser desorption ionization-time of flight mass spec-
trometry (MALDI-TOF MS; Microflex; Bruker Dalton-
ics, Bremen, Germany). The SF testing was performed
as suggested by the manufacturer. All results were
checked manually in the software.
Statistical procedures
A multivariate logistic regression was used to anal-
yse the association of the SF and BC positivity rates
with predicting test variables (clinical indications, as-
signing ward and antimicrobial treatment) after cases
of contamination were removed. The comparison
of SF+/BC– vs. SF–/BC+ for each of the categories
of a test variable was carried out by binomial tests.
A possible impact on the distribution of SF+ vs. SF–
test results was compared for each category using
a χ2-test. To analyse the impact of positive SF results
on the length of ICU stay, total hospital stay, and mor-
tality, ICU patients with single (SF+/BC–) and double
positive (SF+/BC+) test results were matched with
double negative (SF–/BC–) cases with the same gen-
der, age and clinical ward. Matching was performed
using a log-rank test. Patients who died during the
hospital stay were counted as deceased and evaluated
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Table 1 Overviewof posi-
tive test results
Category Positive samples










SF+/BC– 76 (16.2) 44 (10.3) 105 (58.0) 57 (47.5)
SF–/BC+ 22 (4.7) 16 (3.7) 31 (17.1) 22 (18.3)
SF+/BC+ 49 (10.4) 44 (10.3) 45 (24.9) 41 (34.2)
Overall 147 (31.3) 104 (24.4) 181 (100) 120 (100)
SF SeptiFast, BC blood culture
separately using a χ2-test. For all tests an alpha value
of 0.05 was chosen as significance level.
Results
We derived 470 paired BC and SF samples from 398
patients. Only one (paired) sample was submitted
from 345 patients, whereasmultiple sample pairs were
submitted from 53 patients. Multiple pairs from the
same patient came from independent episodes; there-
fore, the samples were treated as independent sam-
ples for our study. In 419 cases, SF and BC samples
were collected from the same blood draw, in 51 cases
from different blood draws (within 24 h). Of the 470
febrile episodes analysed, the clinical indications for
the blood draw were sepsis in 190, endocarditis in
46, FUO in 56, pneumonia in 97, immunosuppression
in 93 (67 with status post-organ transplantation, and
29 with hematological malignancies) and for 16 cases
the exact indication could not be reconstructed. In
110 cases more than one clinical indication for testing
was given. In 147 (31.3%) out of 470 cases at least 1 of
the tests was positive (Table 1). Overall, SF was posi-
tive in 125 (26.6%), and BC in 71 (15.1%) cases. Both
tests were negative in 323 (68.7%), and both were pos-
itive in 49 (10.4%) cases. After exclusion of contami-
nants, a total of 427 cases remained in the study. Of
these, 75.6% yielded double negative results, and 104
(24.4%) positive results, including 44 (10.3%) double
positive results. For 2 of the double positives, mi-
croorganisms identified by SF and BC differed from
each other. In one case, SF revealed Enterobacter spp.
and Klebsiella spp., while BC identified Comamonas
testosteroni, which is not part of the SF panel. In the
other case SF detected Candida albicans (which was
also found in OMS), whereas BC identified Klebsiella
pneumoniae, Enterococcus faecalis, and CoNS. The SF
and BC results agreed in 365 of the 427 (85.5%) cases.
Overall, SF detected a total of 150 microorganisms,
98 of which were considered relevant (65.3%); the vast
majority of positive but irrelevant results were CoNS
detected only by manual interpretation of SF results.
BC detected 76 microorganisms, and 63 were classi-
fied as relevant (82.9%). Thus, of a total of 120 relevant
microorganisms identified, 81.7% were detected by SF,
and 52.5% by BC. In 6 out of 16 cases (6/22 microor-
ganisms, Table 2) in which a potential pathogen was
solely detected by BC, the microorganism was not in-
cluded in the SF master detection list. In the 44 cases
where relevant pathogens were only detected by SF,
57 microorganisms were detected (53 common sep-
sis pathogens and 4 common contaminants), which
were considered as relevant. Of the 53 common sep-
sis pathogens 16 were also detected in at least 1 OMS
(Table 2).
When compared with BC, SF was more likely to
identify Staphylococcus aureus (17/18 vs. 10/18),
Streptococcus pneumoniae (12/12 vs. 3/12), Entero-
coccus faecium (6/8 vs. 2/8), Enterobacter spp. (7/7 vs.
1/7), Candida spp. (12/12 vs. 4/12) and Aspergillus
fumigatus (3/3 vs. 0/3) (Table 2). In 5/8 S. aureus,
8/9 S. pneumoniae, 4/6 E. faecium, 4/6 Enterobacter
spp., 6/8 Candida spp., and 3/3 A. fumigatus cases
found only by SF, antimicrobial agents had been ad-
ministered prior to the blood draws. Antimicrobial
treatment was carried out in 31 of the 44 SF+/BC–
cases with relevant pathogens. Overall, of the 427
uncontaminated sample pairs, 276 (64.6%) were de-
rived from patients under antimicrobial therapy. For
treated patients the number of SF+/BC– outcomes
was significantly higher than that of SF–/BC+ cases
(P < 0.001); this was not found in untreated patients.
The ratio of SF+ to SF– test results did not differ
considerably between the categories therapy and no
therapy (Table 3).
Fig. 1 shows the distribution of SF and BC results
of uncontaminated sample pairs with respect to clin-
ical indications and assigning ward. With respect to
clinical indications, the ratio of SF+ to SF– outcomes
was significantly higher for sepsis and lower for FUO
in comparison to the other categories (Table 3). Fur-
thermore, the number of SF+/BC– cases was signifi-
cantly higher than that of SF–/BC+ outcomes for the
categories sepsis, pneumonia, and immunosuppres-
sion, but lower for endocarditis (Table 3). The ratios
of treated to untreated patients were comparable be-
tween the different categories e. g. 73.7% for sepsis
and 69.6% for endocarditis.
Regarding the variable “ward”, the number of
SF+/BC– test results was significantly higher than
that of SF–/BC+ outcomes (Table 3) in each but the
outpatient wards, where the low number of speci-
mens did not allow for statistical analysis. The ratios
of SF+ to SF– test results were significantly higher for
specimens submitted by the emergency department
and ICUs, and significantly lower for those from in-
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Table 2 Overall distributionof detectedmicroorganisms
Microorganisms Total SF+ BC+ SF+/BC-
(OMS+)
SF-/BC+ SF+/BC+
Gram+ Staphylococcus aureus 18 17 10 8 (2) 1 9
CoNS 9 6 8 1 3 5
Streptococcus spp 4 4 1 3 (1) 0 1
Streptococcus pneumoniae 12 12 3 9 (2) 0 3
Enterococcus faecium 8 6 2 6 (5) 2 0
Enterococcus faecalis 3 2 2 1 1 1
Gram– Escherichia coli 19 16 14 5 (1) 3 11
Klebsiella pneumoniae/Klebsiella oxytoca 9 7 5 4 2 3
Serratia marcescens 1 1 1 0 0 1
Enterobacter cloacae/Enterobacter
aerogenes
7 7 1 6 0 1
Proteus mirabilis 0 0 0 0 0 0
Pseudomonas aeruginosa 7 5 4 3 2 2
Acinetobacter baumannii 1 0 1 0 1 0
Stenotrophomonas maltophilia 1 0 1 0 1 0
Fungi Candida albicans 9 9 3 6 (2) 0 3
Candida tropicalis 2 2 0 2 (1) 0 0
Candida parapsilosis 0 0 0 0 0 0
Candida krusei 1 1 1 0 0 1
Candida glabrata 0 0 0 0 0 0
Aspergillus fumigatus 3 3 0 3 (2) 0 0
Cont. CoNS 56 48 12 44 (1) 8 4
Streptococcus spp 4 4 0 4 0 0
Propionibacterium acnes* 1 0 1 0 1 0
Other Comamonas testosteroni* 1 0 1 0 1 0
Bacteroides spp* 2 0 2 0 2 0
Granulicatella spp* 1 0 1 0 1 0
Listeria monocytogenes* 1 0 1 0 1 0
Prevotella spp* 1 0 1 0 1 0
SF SeptiFast, BC blood culture, OMS+ SeptiFast result confirmed by other microbiological samples, Gram+ relevant gram-positive bacteria, Gram– relevant
gram-negative bacteria, Cont. contaminants, CoNS coagulase-negative staphylococci
* microorganisms not included in the SeptiFast master detection list
ternal medical wards (Table 3). The highest overall
positivity (23/58; 39.7%) and highest rate of SF+/BC+
outcomes (18/58, 31.0%; 100% concordance) but at
the same time, with the exception of outpatient units,
the lowest ratio of treated to untreated patients by
far (35%), was shown for cases from the emergency
department. Multivariate logistic regression analysis
revealed that the percentage of SF+/BC+ cases for the
emergency department was significantly higher (P =
0.007) than that for any of the categories irrespective
of the test variable (Fig. 1).
The 17 SF+/BC+ and 19 SF+/BC– cases from ICUs
were matched with equal numbers of SF–/BC– ICU
cases. Age, gender and clinical ward were used as
matching criteria, the clinical diagnosis and antibiotic
therapy were also comparable between the groups.
When analysing the length of ICU and total hospi-
tal stay no significant differences were found between
SF+/BC+ and SF+/BC– vs. SF–/BC– cases. Deceased
patients were excluded from this analysis. A total of
15/36 (41.7%) patients died in the SF+ vs. 9/36 (25%)
in the SF– cases, 7/19 (36.8%) patients died in the
SF+/BC– vs. only 2/19 (10.5%) in the SF–/BC– control
group and 8/17 (47.1%) patients died in the SF+/BC+
vs. 7/17 (41.2%) in the control group. These differ-
ences were not statistically significant.
Discussion
The present study on patients with sepsis or evidence
of other serious systemic infectious diseases aimed
at the retrospective assessment of the usage of SF in
a routine setting. A particular focus was set on the
association of clinical factors and the assigning ward
with the rate of pathogen identification by SF in com-
parison to BC. This knowledge might contribute to
a more efficient routine application of this molecular
test.
In this retrospective analysis overall positivity rates
of SF and BC and concordance between tests were
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Table 3 Statistical analysis of differencesper test variable
in sampleswith relevantpathogens
Test variable P (SF+/BC– vs.
SF–/BC+)
P (SF+ vs. SF–)
Sepsis <0.001 (+) <0.001 (+)
Endocarditis 0.013 (–) 0.568
FUO 0.125 0.011 (–)
Pneumonia <0.001 (+) 0.202
Immunosuppression <0.001 (+) 0.179
Internal medicine 0.004 (+) 0.003 (–)
Surgery 0.009 (+) 0.089
ICU 0.006 (+) 0.002 (+)
Emergency <0.001 (+) 0.002 (+)
Outpatient n.a. 0.170
Therapy <0.001 (+) 0.779
No therapy 0.089 0.779
P P-value, SF SeptiFast, BC blood culture, (+) significantly higher, (–) signif-
icantly lower, n.a. not available, FUO fever of unknown origin, ICU intensive
care unit
similar to data published in prospective studies [27,
34]. Thus, the positivity rates were 26.6% for SF and
15.1% for BC. After exclusion of contaminants, the
rate of false negative cases in SF was 3.7%, the test
agreement rate 85.5%, and the percentage of cases of
relevant pathogens solely detected by SF 10.3%. While
the rates of relevant pathogens found by SF (82%)
and BC (53%) in the present study were comparable
to other studies, the rate of contaminants detected by
SF was considerably higher than reported previously
[22, 28, 31, 34, 39]. The SF cut-off value for common
contaminants is set higher than that for other bac-
teria to avoid false positive findings due to bacterial
skin flora contamination. Thus, low melting curve
peaks in the spectrum of common contaminants are
normally not identified by the software, and the re-
spective samples are regarded as negatives; however,
according to our routine laboratory guidelines, SF
results are to be interpreted manually. This is due to
our observation that, particularly in the gram-positive
spectrum, pathogens also detected by BC may not be
identified by the SF software due to low melting curve
peaks. Low melting curve peaks corresponding to the
spectrum of CoNS are routinely communicated to the
clinician as possible contamination. In a consider-
able number of BC negative cases relevant pathogens
could only be detected by SF, as also described in
several prospective studies [22–30, 32–34, 36, 38].
Moreover, with the exception of FUO and endocardi-
tis, in other categories the number of SF+/BC– cases
was significantly higher than that of SF–/BC+ cases.
The fact that SF may underperform for patients suf-
fering from endocarditis has been demonstrated by
others [35]. This may be due to several reasons: the
small numbers of pathogens circulating in blood, the
fact that some endocarditis-relevant pathogens (e. g.
those of the HACEK group: Haemophilus spp., Aggre-
gatibacter actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, Kingella kingae) are not
included in the SF panel, or the high cut-off value
for CoNS; however, the last two reasons do not apply
for the present study. Nevertheless, Mencacci et al.
suggest that SF may be a useful tool for the detec-
tion of endocarditis pathogens in patients undergoing
antimicrobial therapy [41].
In agreement with previous studies [24, 27–29, 34,
38], S. aureus, S. pneumoniae, E. faecium, Enterobacter
spp., and fungi were detected more frequently by SF
than BC. In the great majority of SF+/BC– cases with
these pathogens the patients were under antimicro-
bial therapy. This suggests that treatment may, at least
in part, be responsible for this discrepancy. The po-
tential role of antimicrobial therapy is also supported
by the significantly higher number of SF+/BC– cases,
compared to SF–/BC+ cases, in treated patients; how-
ever, the difference in the rate of SF+/BC– test results
between the treated and the untreated group was not
significant. In this respect our data are in line with
studies [22, 38] that demonstrated a higher rate of pos-
itivity of SF for the treated group with the difference,
however, not reaching statistical significance. A sig-
nificant difference has been reported in other studies
[42–44].
In samples submitted from the emergency de-
partment we observed a significantly higher rate of
SF+/BC+ results compared to any other ward. We
also noted that for all SF+/BC+ cases in this group the
SF and BC results were in agreement. This finding
may be due to the following: patients delivered to the
emergency unit have more apparent signs and symp-
toms of sepsis than those admitted to other wards
(e. g. ICUs); therefore, the decision to perform BC
and SF as specific diagnostic measures may be more
obvious. Additionally, these patients usually have
not received antimicrobial therapy, which might con-
tribute to the high overall positivity and agreement
between both tests. Thus, emergency room patients
may benefit most from the rapid results obtained by
SF testing rather than higher test positivity in compar-
ison to BC. Our findings are in accordance with those
by Avolio et al. [23] but diverge from those reported
by Tsalik et al. [31].
Lehmann et al. [27] demonstrated significantly
longer hospital stays (38 vs. 23 days), and a higher
rate of mortality (66% vs. 33%) for patients with
SF+/BC+ vs. SF–/BC– test results. The lack of con-
siderable differences in the length of ICU and total
hospital stays between ICU patients with SF+/BC–
or SF+/BC+ test results and matched SF–/BC– con-
trols in our study may be explained by the fact that
patients with positive test results, while being more
ill, are given a more targeted antibiotic therapy. The
higher rate of mortality for SF+ than SF– patients may
indicate that a positive PCR result is likely to reflect
a severe life-threatening medical condition; however,
these findings need to be considered with appropriate
caution considering the small subset of data analysed.
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Since the introduction of the SF assay several
prospective but only few retrospective studies eval-
uated the benefits and shortcomings of this method
[45–47]. To our knowledge, this study is so far the
only one retrospectively analysing the association
of the test outcome with important factors such as
the indications for testing, assigning ward and an-
timicrobial therapy in comparison to BC; however,
even though retrospective studies may reflect clinical
practice more accurately than prospective controlled
trials, they are more prone to bias. In this context,
it needs to be noted that the decision for SF testing
was solely taken by the responsible clinician. Thus,
a selection bias is likely to have influenced the rate
and types of pathogens found.
SF showed a low rate of false negative results and,
due to its fast turnaround time, proved to be a valu-
able diagnostic add-on to BC. The highest positivity
and concordance between tests was shown in emer-
gency room patients. Overall, in cases of suspected
sepsis, pneumonia, or in immunocompromised pa-
tients with febrile episodes, SF exhibited considerably
higher positivity rates and enabled the rapid detec-
tion of clinically important pathogens not identified
in BC; however, the clinical relevance and significance
of SF+/BC– results need to be interpreted with caution
and closely focused prospective studies are needed to
clarify this important issue:
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